Hormonal contraception and venous thrombosis An up-date

Hormonal contraception and acne

Hormonal contraception and acne Øjvind Lidegaard Dansk Dermatologisk Selskab 15.1.2014 Gynaecological Clinic, Rigshospitalet University of Copenhagen OC generations according to oestrogen dose and progestogen

Hormonal contraception and thrombosis. An update

Hormonal contraception and thrombosis. An update Øjvind Lidegaard Clinical Professor in Obstetrics & Gynaecology Barcelona, Spain, 21.2.2015 Department of Gynaecology, Rigshospitalet Faculty of Health

Oral contraceptives Epidemiological aspects Øjvind Lidegaard

Oral contraceptives Epidemiological aspects Øjvind Lidegaard Professor Gynaecological Clinic 4232 Rigshospitalet Copenhagen University OC: Epidemiological aspects OC use OC and thrombosis - venous thromboembolism

Hormonal contraception and risk of venous thromboembolism: national follow-up study

Hormonal contraception and risk of venous thromboembolism: national follow-up study Øjvind Lidegaard, professor, 1 Ellen Løkkegaard, consultant, 2 Anne Louise Svendsen, statistician, 3 Carsten Agger, data

Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare

Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare New data A paper published in May 2012 in the British Medical Journal

Oral contraception in Denmark

A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Oral contraception in Denmark 1998 2010 NADIA M. WILSON 1, MAJA LAURSEN 2 & ØJVIND LIDEGAARD 1 1 Gynecological Clinic, Rigshospitalet University

Appendix A Materials Considered by Dr. Shelley Tischkau In addition to the materials specifically referenced in my report, the other materials I have considered are: Literature Editorial: Sex Hormone Binding

Contraccezione e tromboembolismo venoso

Contraccezione e tromboembolismo venoso Ida Martinelli Centro Emofilia e Trombosi Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico - Milano XXVII Congresso Nazionale FCSA Milano, 20-22.10.2016

Trudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins

1 Women's Health 2015: The 23rd Annual Congress FRIDAY, April 17, 2015 Trudy Bush Lecture: Using Progestins in Clinical Practice Commercial Disclosure: I am a consultant on litigation relating to the Mirena

Early release, published at on November 7, Subject to revision.

CMAJ Early release, published at www.cmaj.ca on November 7, 2011. Subject to revision. Research Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based

When talking about CHC it should not be forgotten that in addition to providing contraception this contraceptive method is associated with additional

1 2 When talking about CHC it should not be forgotten that in addition to providing contraception this contraceptive method is associated with additional health benefits. These benefits can be used to

RESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2

TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status

Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception

T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception Øjvind Lidegaard, Dr. Med. Sci., Ellen Løkkegaard, Ph.D.,

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous

Learning objectives. Some fun facts. Presenter Disclosure Information. Become familiar with the newest contraceptive options available

8:45 9:30 am Advances and Options in Female Contraception SPEAKER Pelin Batur, MD, FACP, NCMP, CCD Presenter Disclosure Information The following relationships exist related to this presentation: Pelin

Key words: APC resistance/oral contraceptives/shbg/venous thrombosis. doi: /humrep/deh612

Human Reproduction Vol.20, No.2 pp. 563 568, 2005 Advance Access publication November 11, 2004. doi:10.1093/humrep/deh612 Association between sex hormone-binding globulin levels and activated protein C

CURRENT HORMONAL CONTRACEPTION - LIMITATIONS

CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception

Elements for a Public Summary. VI.2.1 Overview of Disease Epidemiology

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Etonogestrel/ethinylestradiol vaginal delivery system is a vaginal ring form of birth control used to prevent unplanned pregnancy

CONTRACEPTION AND MISCONCEPTIONS CONTRACEPTION IN WOMEN WITH MENTAL ILLNESS

CONTRACEPTION AND MISCONCEPTIONS CONTRACEPTION IN WOMEN WITH MENTAL ILLNESS OVERVIEW Hormones and mood How mental illness impacts on contraceptive choice Ideal contraception Pro and cons of contraceptive

Elements for a Public Summary. Overview of Disease Epidemiology

VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Etonogestrel/ethinylestradiol vaginal delivery system is a vaginal ring form of birth control used to prevent unplanned pregnancy

Learning objectives. Some fun facts. Presenter Disclosure Information. Discuss the newest contraceptive options available

2:15 3pm Advances and Options in Female Contraception SPEAKER Pelin Batur, MD, FACP, NCMP, CCD Presenter Disclosure Information The following relationships exist related to this presentation: Pelin Batur,

1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis

1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet

Menopausal Hormone Therapy & Haemostasis

Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen

Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases

open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of

Cancer and blood clots

n The Leeds Teaching Hospitals NHS Trust Cancer and blood clots What you should know whilst you are in source isolation Information for thyroid patients Please read this leaflet carefully. It will give

Complex Medical Problems? Complex Contraception. Objectives 4/17/2015. Sari Kives, MD,FRCSC ; Alene Toulany, MD, FRCPC

Complex Medical Problems? Complex Contraception Sari Kives, MD,FRCSC ; Alene Toulany, MD, FRCPC Objectives Identify contraceptive options for an adolescent with Thrombophelia Diabetes SLE Migraines Epilepsy

2

1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive

PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Disclosures. Objectives/Discussion Points 6/2/2017

PRESCRIBING HORMONAL CONTRACEPTIVES TO WOMEN WITH MIGRAINE (CON) Gretchen E. Tietjen, MD Department of Neurology University of Toledo Disclosures Advisory Boards: Eli Lilly, Dr. Reddy s Common Stock: J&J,

Haemostasis, thrombosis risk and hormone replacement therapy

Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis

Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics

Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics Advice from the Tayside Sexual & Reproductive Health Service (TSRHS) (Last update: 10/2017) Combined hormonal

Instruction for the patient

WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic

Birth Control in Patients with Congenital Heart Disease

Birth Control in Patients with Congenital Heart Disease Arwa Saidi MB. BCh. MEd. FACC University of Florida Departments of Pediatrics and Internal Medicine Gainesville, FL There are an increasing number

BMI and Contraception: What s the Evidence?

BMI and Contraception: What s the Evidence? Kathryn M. Curtis, PhD Division of Reproductive Health Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion

Explaining Contraceptive Risks. Update on Medical Eligibility Criteria for Contraceptive Use

Beth Kutler FNP Explaining Contraceptive Risks Update on Medical Eligibility Criteria for Contraceptive Use Questions in Contraception Transdermal patch DMPA Drug Interactions IUDs Case Studies While I

Sinus and Cerebral Vein Thrombosis

Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What

Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication

Dianette (cyproterone acetate 2mg/ethinylestradiol 35 mcg): Strengthening of warnings, new contraindications, and updated indication Dear Healthcare Professional, In agreement with the European Medicines

UKMEC SUMMARY TABLE HORMONAL AND INTRAUTERINE CONTRACEPTION

SUMMARY TABLE SUMMARY TABLE HORMONAL AND INTRAUTERINE CONTRACEPTION Cu-IUD = Copper-bearing intrauterine device; LNG-IUS = Levonorgestrel-releasing intrauterine system; IMP = Progestogen-only implant;

Combined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases

Combined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Web appendix:

Hormone therapy (HT) Epidemiological aspects

Hormone therapy (HT) Epidemiological aspects Øjvind Lidegaard Professor, DMSc Gynaecological Clinic 4232 Rigshospitalet Copenhagen University www.lidegaard.dk/slides Hormone therapy; an update Hormone

Use of hormonal therapy in acne

Acne Guidelines Use of hormonal therapy in acne Julie C Harper MD Conflict of Interest Disclosure Speaker/Advisor Allergan Bayer Galderma Valeant Investigator Bayer Our task: What is the effectiveness

Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes

Diabetes Care 1 Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes Sarah H. O Brien, 1,2 Terah Koch, 2 Sara K. Vesely, 3 and Eleanor Bimla Schwarz 4 DOI: 10.2337/dc16-1534 OBJECTIVE

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service

HIV and contraception the latest recommendations

1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for

Progestin-only methods Type or dose of progestagen

Progestin-only contraception and beneficial effects on migraine Conflicts of interest A d v ise r a n d le ctu re r fo r E X E LT IS Le ctu re s a n d A d v iso ry b o a rd s B aye r Le ctu re s a n d

PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...

Table of contents Summary tables PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...3 Past ectopic pregnancy...3 History

RESEARCH INTRODUCTION ABSTRACT

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database Lianne Parkin, senior

Instructions how to use the ESC teach the teachers course and self-learning tool

Instructions how to use the ESC teach the teachers course and self-learning tool Welcome to the ESC advanced learning tool To improve and facilitate knowledge and use of contraception, abortion, sexually

VI.2. ELEMENTS FOR A PUBLIC SUMMARY

VI.2. ELEMENTS FOR A PUBLIC SUMMARY VI.2.1 Overview of Disease Epidemiology COCs containing DRSP-EE are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Division of Reproductive Health Centers for Disease Control and Prevention August 1, 2013 National Center for Chronic Disease Prevention and

February 6, Dear Dr. Von Eschenbach:

Petition to the FDA to Ban Third Generation Oral Contraceptives Containing Desogestrel due to Increased Risk of Venous Thrombosis (HRG Publication #I799) February 6, 2007 Andrew Von Eschenbach, M.D., Commissioner

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck

ADOLESCENT CONTRACEPTION UPDATE APRIL 28, 2017 Brandy Mitchell, MN, RN, ANP BC, WHNP BC University of Iowa Hospitals and Clinics Obstetrics and Gynecology Iowa Association of Nurse Practitioners Spring

Are there still any valid indications for thrombophilia screening in DVT?

Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

LARC: Long Acting Reversible Contraception Disclosures I have no relevant financial disclosures Jennifer Kerns, MD, MPH Assistant Professor, UCSF Obstetrics, Gynecology and Reproductive Sciences San Francisco

International Federation of Gynecology and Obstetrics

International Federation of Gynecology and Obstetrics THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION THE ROLE OF POST- ABORTION CONTRACEPTION IN PREVENTION OF UNSAFE ABORTION

2

1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive

Medical Eligibility for Contraception Use

Medical Eligibility for Contraception Use DIVISION OF REPRODUCTIVE HEALTH CENTERS FOR DISEASE CONTROL AND PREVENTION 2016 US Medical Eligibility Criteria for Contraceptive Use (US MEC) Purpose To assist

Instructions how to use the ESC teach the teachers course and self-learning tool

Instructions how to use the ESC teach the teachers course and self-learning tool Welcome to the ESC advanced learning tool To improve and facilitate knowledge and use of contraception, abortion, sexually

Causative factors of deep vein thrombosis of lower limb in Indian population

International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative

Chapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy

Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer

IMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS:

Article DOI: 10.2478/v10133-010-0054-y MB IMPACT OF ORAL CONTRACEPTIVES AND SMOKING ON ARTERIAL AND DEEP VENOUS THROMBOSIS: А RETROSPECTIVE case-control STUDY V. Tzankova 1, V. Petrov 2 and N. Danchev

CONTRACEPTION DISCLOSURES OBJECTIVES ACKNOWLEDGEMENTS AND SEXUAL FUNCTION 10/21/2014

CONTRACEPTION AND SEXUAL FUNCTION Susan Kellogg Spadt, PhD, CRNP,IF,FCST Director: Female Sexual Medicine Academic Urology Center for Pelvic Medicine Bryn Mawr Pa Prof. OBGYN: Drexel University College

World Health Organization Medical Eligibility for Contraceptive Use. Connie Kraus, PharmD, BCACP Professor (CHS) Director Office of Global Health

World Health Organization Medical Eligibility for Contraceptive Use Connie Kraus, PharmD, BCACP Professor (CHS) Director Office of Global Health Objectives After this session, learners should be able to:

Contraception for young people. Dr Cindy Farmer Bristol Sexual Health Services Fri 8 th May 2015

Contraception for young people Dr Cindy Farmer Bristol Sexual Health Services Fri 8 th May 2015 Learning objectives Be able to apply the principles of confidentiality, Fraser Guidelines, consent and safeguarding

RESEARCH. open access ABSTRACT. Introduction About 104 million women worldwide use oral contraceptives. 1 In most countries various types of pills are

open access Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study Alain Weill, 1 Marie Dalichampt,

Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016

Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016 Disclosure I am a Nexplanon trainer for Merck. Objectives Understand how obesity may affect pharmacokinetics

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community Reproductive Health 2012 September 21, 2012 David Turok, MD/MPH Objectives Communicate to colleagues the reduction

THROMBOSIS RISK FACTOR ASSESSMENT

Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations Emily M. Godfrey, MD MPH Associate Professor, Departments of Family Medicine and Obstetrics and Gynecology, University of Washington, Seattle WA Guest Researcher,

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations Emily M. Godfrey, MD MPH Associate Professor, Departments of Family Medicine and Obstetrics and Gynecology, University of Washington, Seattle WA Guest Researcher,

Pulmonary hypertension; does gender matter?

Pulmonary hypertension; does gender matter? Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it Galiè N et al. European Heart Journal (2009) 30, 2493 2537 Pulmonary Hypertension

Clinical effects of adding DHEA to the pill

Clinical effects of adding DHEA to the pill Roumen FJME, van Wijck A, Zimmerman XY, Beekman L, ter Kuile MM, Coelingh Bennink HJT Atrium Medical Center Parkstad, Heerlen Leiden University Medical Center

Deep Vein Thrombosis and Pulmonary Embolism: Patient Information

Deep Vein Thrombosis and Pulmonary Embolism: Patient Information A Deep Vein Thrombosis (DVT) and a Pulmonary Embolism (PE) are both disorders of unwanted blood clotting. Unwanted blood clots can occur

Page 1 of 46. DROSPIRENONE, ETHINYL ESTRADIOL and LEVOMEFOLATE CALCIUM Tablets and LEVOMEFOLATE CALCIUM Tablets, for oral use

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets

Orals,Transdermals, and Other Estrogens in the Perimenopause

Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter

HORMONE REPLACEMENT THERAPY

TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

Contraception and gynecological pathologies

1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about

Contraception in the medically complicated patient

Contraception in the medically complicated patient Sarita Sonalkar, MD MPH Assistant Professor Department of Obstetrics and Gynecology University of Pennsylvania Disclosures } Consultant for World Health

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)

Contraception for Women With Chronic Medical Conditions

This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2016 ~ Resource #320901 Contraception for

Differences in the use of combined oral contraceptives amongst women with and without acne

Human Reproduction Vol.18, No.3 pp. 515±521, 2003 DOI: 10.1093/humrep/deg090 Differences in the use of combined oral contraceptives amongst women with and without acne H.E.Seaman 1, C.S.de Vries and R.D.T.Farmer

BEST PRACTICES IN CONTRACEPTIVE COUNSELING

Condition Sub-condition Combined pill, patch, ring Anemias a) Thalassemia 1 1 1 1 1 2 b) Sickle cell disease 2 1 1 1 1 2 c) Iron-deficiency anemia 1 1 1 1 1 2 Benign ovarian (including cysts) 1 1 1 1 1

Clinical Challenges in Contraception. Disclosures. Objectives Pharmacists 4/3/2018

Clinical Challenges in Contraception Kathleen Besinque, PharmD Sarah McBane, PharmD Disclosures Kathleen Besinque has nothing to disclose Sarah McBane has nothing to disclose Objectives Pharmacists Compare

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page The handle http://hdl.handle.net/1887/19768 holds various files of this Leiden University dissertation. Author: Langevelde, Kirsten van Title: Are pulmonary embolism and deepvein thrombosis

Causal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra

Causal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra B. Burt Gerstman June 2008 This brief document addresses the question Does Ortho Evra cause more cardiovascular

Sex Differences in Stroke Risk and Quality of Life after Stroke

Sex Differences in Stroke Risk and Quality of Life after Stroke Cheryl Bushnell, MD, MHS Associate Professor of Neurology Director, WFB Stroke Center Disclosures Research funding from: World Federation

prevalence was 13.8% among females

1 2 3 1. Woldeamanuel YW et al. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of communitybased studies involving 6 million participants. J Neurol

Conclusions: the relative safety of modern oral contraceptives

Human Reproduction Update 1999, Vol. 5, No.6 pp. 756-771 European Society oj Human Reproduction and Embryology Conclusions: the relative safety of modern oral contraceptives Jean Cohen 1 and R.G.Edwards

Prescriber Guide for the Letairis REMS Program

LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:

Breast Cancer Risk in Patients Using Hormonal Contraception

Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion:

Contraceptive case studies. Dr Christine Roke National Medical Advisor Family Planning June 2015

Contraceptive case studies Dr Christine Roke National Medical Advisor Family Planning June 2015 Case 1 Mary is a 47 year old who has come in for a routine cervical smear. She asks when her Multiload IUD

Implants and ART: weighing the evidence to guide programs

Implants and ART: weighing the evidence to guide programs Presented by: Jennifer Mason, MPH; Tabitha Sripipitana, MPH; and Sarah Yeiser, MPH Office of Population & Reproductive Health, USAID Office of

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able

Increasing the Proportion of Women using Long Acting Reversible Contraception (LARC) within a Geographical Area in Scotland

Increasing the Proportion of Women using Long Acting Reversible Contraception (LARC) within a Geographical Area in Scotland Dr Audrey Brown Dr Alison Bigrigg Greater Glasgow and Clyde Long-acting reversible

Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study

IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after

Topics. BRCA 1 and BRCA 2 Mutations. Breast cancer BRCA1 / BRCA BRCA 1 und BRCA 2 Mutations and hormonal therapy

BRCA 1 and BRCA 2 Mutations Recommendations for Contraception PD G.Merki USZ Breast Cancer risk Topics Breast Cancer risk and hormonal Contraception BRCA 1/2 mutations and changes in risk for breast and